In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Diffusion Pharmaceuticals Inc (DFFN), with a price target of $1.25. The company’s shares closed yesterday at $0.32, close to its 52-week low of $0.31.
Ramakanth noted:
“We maintain our Buy rating of DFFN and our 12-month price target of $1.25 per share. We derive our price target based on a risk-adjusted NPV analysis of projected TSC revenues through 2030 assuming a 12% discount rate and 2% terminal growth rate.”
According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -1.8% and a 33.2% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as IntelGenx Technologies, Leap Therapeutics Inc, and Tyme Technologies Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Diffusion Pharmaceuticals Inc with a $1.25 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.08 and a one-year low of $0.31. Currently, Diffusion Pharmaceuticals Inc has an average volume of 246.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Diffusion Pharmaceuticals, Inc. is a clinical stage company which engages in the provision of oncology-focused biotechnology. It involves in research and development, and manufacture of drug products for the treatment of cancer in combination with radiation and chemotherapy.